WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529608

CAS#: 10356-76-0

Description: FdCyd is a DNA methyltransferase (DNMT) inhibitor potentially for the treatment of solid tumours.

Price and Availability


USD 260

USD 470

USD 820

FdCyd, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 529608
Name: FdCyd
CAS#: 10356-76-0
Chemical Formula: C9H12FN3O4
Exact Mass: 245.0812
Molecular Weight: 245.21
Elemental Analysis: C, 44.08; H, 4.93; F, 7.75; N, 17.14; O, 26.10

Synonym: NSC-48006; Ro-5-1090; FdCyd; NSC48006; Ro51090; NSC 48006; Ro 5 1090

IUPAC/Chemical Name: 4-amino-5-fluoro-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one


InChi Code: InChI=1S/C9H12FN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1

SMILES Code: OC[C@@H]1[C@H](C[C@H](N2C(N=C(C(F)=C2)N)=O)O1)O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Holleran JL, Eiseman JL, Parise RA, Kummar S, Beumer JH. LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. J Pharm Biomed Anal. 2016 Sep 10;129:359-66. doi: 10.1016/j.jpba.2016.07.027. PubMed PMID: 27454087; PubMed Central PMCID: PMC5003709.

2: Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8. PubMed PMID: 17899082.

3: Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. PubMed PMID: 25567350; PubMed Central PMCID: PMC4344391.

4: Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans. Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x. PubMed PMID: 26321472; PubMed Central PMCID: PMC4573928.

5: Guo D, Myrdal PB, Karlage KL, O'Connell SP, Wissinger TJ, Tabibi SE, Yalkowsky SH. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination. AAPS PharmSciTech. 2010 Mar;11(1):247-52. doi: 10.1208/s12249-010-9383-2. PubMed PMID: 20151336; PubMed Central PMCID: PMC2850501.

6: Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Clin Cancer Res. 2006 Dec 15;12(24):7483-91. PubMed PMID: 17138702.

7: Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. J Neurooncol. 2016 Jan;126(2):225-34. doi: 10.1007/s11060-015-1965-0. PubMed PMID: 26518542; PubMed Central PMCID: PMC4718940.

8: Pan Y, Daito T, Sasaki Y, Chung YH, Xing X, Pondugula S, Swamidass SJ, Wang T, Kim AH, Yano H. Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity. Sci Rep. 2016 Aug 12;6:31022. doi: 10.1038/srep31022. PubMed PMID: 27516062; PubMed Central PMCID: PMC4981892.

9: Mekras JA, Boothman DA, Perez LM, Greer S. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Res. 1984 Jun;44(6):2551-60. PubMed PMID: 6539164.

10: Boothman DA, Briggle TV, Greer S. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755. Cancer Res. 1987 May 1;47(9):2344-53. PubMed PMID: 2436761.

11: Kaysen J, Spriggs D, Kufe D. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res. 1986 Sep;46(9):4534-8. PubMed PMID: 2425957.

12: Boothman DA, Briggle TV, Greer S. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Cancer Res. 1987 May 1;47(9):2354-62. PubMed PMID: 2952263.

13: Li LS, Morales JC, Veigl M, Sedwick D, Greer S, Meyers M, Wagner M, Fishel R, Boothman DA. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol. 2009 Oct;158(3):679-92. doi: 10.1111/j.1476-5381.2009.00423.x. Review. PubMed PMID: 19775280; PubMed Central PMCID: PMC2765589.

14: Vandamme B, Liebaers I, Hens L, Bernheim JL, Roobol C. The role of fluorinated pyrimidine analogues in the induction of the in vitro expression of the fragile X chromosome. Hum Genet. 1988 Aug;79(4):341-6. PubMed PMID: 2970425.

15: Newman EM, Santi DV. Metabolism and mechanism of action of 5-fluorodeoxycytidine. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23. PubMed PMID: 6959127; PubMed Central PMCID: PMC347137.

16: Iigo M, Yamaizumi Z, Nishimura S, Hoshi A. Elevation of plasma levels of fluorinated pyrimidines by guanosine 5'-monophosphate. Cancer Chemother Pharmacol. 1987;20(1):1-4. PubMed PMID: 3040286.

17: Briggle TV, Boothman DA, Pfaffenberger CD, Greer S. Analysis of 5-fluoro-2'-deoxycytidine and 5-trifluoromethyl-2'-deoxycytidine and their related antimetabolites by high-performance liquid chromatography. J Chromatogr. 1986 Sep 5;381(2):343-55. PubMed PMID: 2944908.

18: Osterman DG, DePillis GD, Wu JC, Matsuda A, Santi DV. 5-Fluorocytosine in DNA is a mechanism-based inhibitor of HhaI methylase. Biochemistry. 1988 Jul 12;27(14):5204-10. PubMed PMID: 3167042.

19: Janion C. On the ability of Salmonella typhimurium cells to form deoxycytidine nucleotides. Mol Gen Genet. 1977 Jun 8;153(2):179-83. PubMed PMID: 329115.

20: De Clercq E, Bères J, Bentrude WG. Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase. Mol Pharmacol. 1987 Aug;32(1):286-92. PubMed PMID: 3039343.